Semaglutide drug Wegovy has been available in New Zealand for a couple of months now, and more Kiwis are learning about the effects.

The drug has transformed our ability to manage obesity and type 2 diabetes, and has shown potential for a wide range of conditions such as Alzheimer’s, addiction and depression.

General Practice NZ chair Dr Bryan Betty joined the Afternoons team to discuss further - and highlight some potential drawbacks.

LISTEN ABOVE

See omnystudio.com/listener for privacy information.